Pharmaceuticals 2019, 12, 161
17 of 19
8.
Chang, L.C.; Hsieh, M.T.; Yang, J.S.; Lu, C.C.; Tsai, F.J.; Tsao, J.W.; Chiu, Y.J.; Kuo, S.C.; Lee, K.H. Effect of bis
(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic
pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study. Int. J. Oncol. 2018
,
9.
Nagahama, K.; Utsumi, T.; Kumano, T.; Maekawa, S.; Oyama, N.; Kawakami, J. Discovery of a new function
of curcumin which enhances its anticancer therapeutic potency. Sci. Rep. 2016, 6, 30962. [CrossRef]
10. Willenbacher, E.; Khan, S.Z.; Mujica, S.C.A.; Trapani, D.; Hussain, S.; Wolf, D.; Willenbacher, W.; Spizzo, G.;
Seeber, A. Curcumin: New Insights into an Ancient Ingredient against Cancer. Int. J. Mol. Sci. 2019, 20, 1808.
11. Anand, P.; Sundaram, C.; Jhurani, S.; Kunnumakkara, A.B.; Aggarwal, B.B. Curcumin and cancer: An “old-age”
disease with an “age-old” solution. Cancer Lett. 2008, 267, 133–164. [CrossRef] [PubMed]
12. Song, X.; Zhang, M.; Dai, E.; Luo, Y. Molecular targets of curcumin in breast cancer (Review). Mol. Med. Rep.
13. Notarbartolo, M.; Poma, P.; Perri, D.; Dusonchet, L.; Cervello, M.; D’Alessandro, N. Antitumor effects of
curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of
their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett.
14. Kouhpeikar, H.; Butler, A.E.; Bamian, F.; Barreto, G.E.; Majeed, M.; Sahebkar, A. Curcumin as a therapeutic
agent in leukemia. J. Cell. Physiol. 2019, 234, 12404–12414. [CrossRef] [PubMed]
15. Gomez-Bougie, P.; Halliez, M.; Maïga, S.; Godon, C.; Kervoëlen, C.; Pellat-Deceunynck, C.; Moreau, P.;
Amiot, M. Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor
prognosis subgroups. Cancer Biol. Ther. 2015, 16, 60–65. [CrossRef]
16. Wang, J.Y.; Wang, X.; Wang, X.J.; Zheng, B.Z.; Wang, Y.; Wang, X.; Liang, B. Curcumin inhibits the growth via
Wnt/β-catenin pathway in non-small-cell lung cancer cells. Eur. Rev. Med. Pharm. Sci. 2018, 22, 7492–7499.
17. Zhang, C.; Hao, Y.; Wu, L.; Dong, X.; Jiang, N.; Cong, B.; Liu, J.; Zhang, W.; Tang, D.; De Perrot, M.; et al.
Curcumin induces apoptosis and inhibits angiogenesis in murine malignant mesothelioma. Int. J. Oncol.
18. Khandelwal, A.R.; Moore-Medlin, T.; Ekshyyan, O.; Gu, X.; Abreo, F.; Nathan, C.O. Local and systemic
Curcumin C3 complex inhibits 4NQO-induced oral tumorigenesis via modulating FGF-2/FGFR-2 activation.
Am. J. Cancer Res. 2018, 8, 2538–2547.
19. Mahammedi, H.; Planchat, E.; Pouget, M.; Durando, X.; Curé, H.; Guy, L.; Van-Praagh, I.; Savareux, L.;
Atger, M.; Bayet-Robert, M.; et al. The New Combination Docetaxel, Prednisone and Curcumin in Patients
with Castration-Resistant Prostate Cancer: A Pilot Phase II Study. Oncology 2016, 90, 69–78. [CrossRef]
20. Killian, P.H.; Kronski, E.; Michalik, K.M.; Barbieri, O.; Astigiano, S.; Sommerhoff, C.P.; Pfeffer, U.; Nerlich, A.G.;
Bachmeier, B.E. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines
CXCL1 and -2. Carcinogenesis 2012, 33, 2507–2519. [CrossRef]
21. Shahcheraghi, S.H.; Zangui, M.; Lotfi, M.; Ghayour-Mobarhan, M.; Ghorbani, A.; Jaliani, H.Z.;
Sadeghnia, H.R.; Sahebkar, A. Therapeutic Potential of Curcumin in the Treatment of Glioblastoma Multiforme.
22. Gersey, Z.C.; Rodriguez, G.A.; Barbarite, E.; Sanchez, A.; Walters, W.M.; Ohaeto, K.C.; Komotar, R.J.;
Graham, R.M. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of
23. Poma, P.; Notarbartolo, M.; Labbozzetta, M.; Maurici, A.; Carina, V.; Alaimo, A.; Rizzi, M.; Simoni, D.;
D’Alessandro, N. The antitumor activities of curcumin and of its isoxazole analogue are not affected by
multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: Analysis of the
possible molecular basis. Int. J. Mol. Med. 2007, 20, 329–335. [CrossRef] [PubMed]
24. Simoni, D.; Rizzi, M.; Rondanin, R.; Baruchello, R.; Marchetti, P.; Invidiata, F.P.; Labbozzetta, M.; Poma, P.;
Carina, V.; Notarbartolo, M.; et al. Antitumor effects of curcumin and structurally beta-diketone modified
analogs on multidrug resistant cancer cells. Bioorg. Med. Chem. Lett. 2008, 18, 845–849. [CrossRef]